Hepatitis B virus persistence in mice reveals IL-21 and IL-33 as regulators of viral clearance

Zhongliang Shen1,2, Huijuan Yang1, Sisi Yang2, Wei Wang1, Xiaoxian Cui1, Xian Zhou1, Wei Liu1, Shaokun Pan1, Yanfeng Liu1,3, Junqi Zhang1, Jiming Zhang1,2, Youhua Xie1 & Jing Liu1

Hepatitis B virus (HBV) generally causes self-limiting infection in immunocompetent adults, but establishes chronic infection in some adults and in most maternally infected infants. Factors determining clearance versus persistence are not fully understood. Hydrodynamic injection (HDI) of HBV replicon plasmid via tail vein generally results in quick clearance in immunocompetent adult mice. Here, we report the identification of strain-specific persistence of HBV in mice: one genotype B strain, designated BPS, persisted up to 33 weeks in ~50% of HDI mice. BPS persistence requires viral replication and multiple viral features. Compared to quickly cleared strains, BPS fails to induce robust post-exposure serum IL-21/IL-33 responses. Injection of IL-21-expressing or IL-33-expressing plasmids facilitates clearance of pre-established BPS persistence and protects cured mice from BPS re-challenge. IL-21 and IL-33 also induce clearance of pre-established HBV persistence in another mouse model. These data reveal IL-21 and IL-33 as potent regulators of HBV clearance and valid drug candidates.

DOI: 10.1038/s41467-017-02304-7
Hepatitis B virus (HBV) takes humans as its sole natural host and exclusively infects hepatocytes in vivo. Infection of naïve adults is usually asymptomatic or subclinical, with 95% of symptomatic infections being self-limited, and the remaining 5% developing life-long chronicity. In contrast, nearly 90% of neonates and approximately 30% of children aged 1–5 years old progress to chronicity upon infection. Chronic HBV infection is associated with higher risks of cirrhosis and hepatocellular carcinoma. World Health Organisation estimated that HBV chronically infects ~240 million people worldwide and causes ~686,000 related deaths annually.

Clinical indicators of recovery from acute hepatitis B, or failure of HBV to establish persistent infection, include loss of serum HBsAg and viral DNA, and appearance of HBsAb. Host and/or viral factors determining clearance vs. persistence are not fully understood, partially due to scarcity of ideal animal models. Although chimpanzees develop chronic infection after experimental exposure, routine use of this host is impractical. Mice are resistant to HBV infection, and transgenic mice expressing human HBV receptor NTCP apparently do not support infection either. However, transfected HBV genome is capable of expression and replication in mouse hepatocytes and murine models taking advantage of this fact are routinely used for characterising host–HBV interactions. For example, recent data linked age-dependent high chronicity rate in young mice to lower HBV-dependent IL-21 production and immature gut microbiota. In comparison, such models have offered fairly limited information on HBV persistence in adults, mostly because adult mice of common immunocompetent strains, including BALB/c and C57BL/6, clear HBV serum markers very quickly after HBV genome plasmids were delivered via hydrodynamic injection (HDI). So far, relative persistence in naïve immunocompetent adult mice has only been observed when adeno-associated virus (AAV) or lentiviral sequences were included in delivery plasmid, or when low doses of recombinant adenovirus or AAV vectors were used for delivery. These models have enabled studying mechanisms of HBV persistence and developing novel therapeutics, but it’s difficult to evaluate roles played by non-HBV viral elements in the observed effects, either directly or through interplay with HBV and/or host functions.

Here, we report the persistence of a clinical strain of genotype B HBV (designated BPS for ‘genotype B persistent strain’) in both BALB/c and C57BL/6 HDI mice without requiring non-HBV viral sequences. We characterised BPS-based HBV persistence mouse model by attempting to identify persistence-related viral and host factors, which showed IL-21 and IL-33 as potent inducers of HBV clearance and promising drug candidates.

**Results**

A clinical HBV isolate displays unique persistence in mice. To reproduce previous results regarding HBV HDI in immunocompetent adult mice, we hydrodynamically injected BALB/c mice with 1.3-fold over-length HBV genome on pUC18 backbone (Supplementary Table 1; Supplementary Fig. 1). Serum HBV antigens were measured in-house using ELISA and confirmed by commercial quantitative assay (Supplementary Fig. 2). As shown in Fig. 1, two genotype B clinical isolates (B6 and B200) were quickly cleared: serum HBsAg peaked at around 1 w.p.i. (weeks post injection), decreased thereafter and disappeared by 2 and 4 w.p.i. (Fig. 1a). Serum HBeAg followed a similar course and disappeared by 4 and 6 w.p.i. (Fig. 1b). Correspondingly, serum HBV DNA decreased from 1 w.p.i. onwards and became virtually undetectable by 8 w.p.i. (Fig. 1c). A panel of common non-B genotype strains also displayed similar quick clearance of HBsAg (Supplementary Fig. 3). These results agreed with previous data showing that HBV replicon plasmids without AAV-derived sequences could not persist in immunocompetent mice.

One genotype B isolate designated BPS, however, displayed surprising persistence: serum antigens peaked at around 1 w.p.i. and started decreasing afterwards similarly to B6/B200, but persisted at considerable levels at 12 w.p.i. in 60% of BPS-injected mice (Fig. 1a, b). Serum HBV DNA also persisted close to 1 w.p.i. levels (Fig. 1c). Furthermore, in repeated experiments with extended follow-up, serum HBV antigens and DNA remained positive up to 33 w.p.i. in half of BPS-injected mice, although antigen levels had decreased remarkably compared to 12 w.p.i. (Supplementary Fig. 4a–c). Immunohistochemistry also confirmed liver HBsAg expression in BPS HDI mice positive for serum HBsAg up to 33 w.p.i. (Fig. 1e; Supplementary Fig. 4d).

All HDI mice displayed an acute, quickly resolved surge of serum ALT at day 1 p.i., most likely caused by HDI procedure. Afterwards, B6 and B200 HDI mice manifested ALT elevations at 2 and 4 w.p.i., respectively, which reverted to normal levels by 4 and 6 w.p.i. (Fig. 1d), coinciding with disappearance of serum HBV antigens and DNA (Fig. 1a–c). In contrast, BPS HDI mice displayed only marginal ALT elevations following post-HDI ALT surge (Fig. 1d). Histochemistry performed on liver sections taken from HDI mice at 1 w.p.i. also showed marked immune infiltration in B6, but not BPS HDI mice, with similar HBV antigen staining in both (Supplementary Fig. 5). Such continued HBV expression and replication without sustained liver damage in BPS HDI mice is reminiscent of the inactive/immunotolerant chronic carrier state in human.

In mice harbouring BPS persistence, injected plasmid DNA in nuclei of liver cells serve as viral transcription templates without involvement of non-liver tissues, formation of cccDNA or chromosomal integration, which is identical to the situation in B6 HDI mice prior to clearance (Supplementary Fig. 6; Supplementary Table 2).

**Virological characterisation of BPS.** Since similar persistence of BPS and quick clearance of B6/B200 were also observed in C57BL/6 mice (Supplementary Fig. 7), BPS persistence is most likely attributable to strain-specific viral features. Sequence alignment between BPS, B6 and B200 identified multiple amino acid differences in all ORFs, except preC, and nucleotide differences in all promoters and enhancers (Supplementary Tables 3, 4). BPS lacks preS2 start codon, but possesses no previously unreported variation. In transfected Huh7 cells, BPS secreted more HBsAg, but similar HBeAg, compared to B6 and B200, and displayed lower replication (Fig. 2). Virions produced by BPS-transfected Huh7 cells displayed no defect in infecting HepG2/NTCP cells (Supplementary Fig. 8). Clinical data on the origin patient of BPS showed no striking peculiarities either (Supplementary Table 1).

BPS persistence requires multiple viral features. Roles of BPS features in persistence were then studied through targeted mutagenesis. Firstly, mutants with polymerase (BPS/εnull), epsilon packaging signal (BPS/e2null), or HBcAg/HBeAg ORF (BPS/Cnull) obliterated were created (Supplementary Fig. 1), which displayed slightly decreased antigen secretion in transfected cells (Fig. 3a, b). Since polymerase, epsilon-mediated cis-packaging of pregenomic RNA by polymerase, and coating of pregenomic RNA/polymerase complex by HBcAg are essential for replication, these mutants were expectedly replication-deficient (Fig. 3c). HDI of BPS/Cnull and BPS/e2null resulted in markedly lower levels of serum antigens, which disappeared in all BPS/Pnull-injected mice by 10 w.p.i., and 6 of 7 BPS/e2null-injected mice by 16 w.p.i. (Fig. 3d). BPS/Cnull-injected mice also manifested
lower serum HBsAg, but clearance rate at 16 w.p.i. was comparable to BPS (Fig. 3d). However, 6 of 7 BPS/C\textsuperscript{null} injected mice cleared HBsAg by 20 w.p.i. (Supplementary Fig. 9). Clearly, BPS persistence requires viral replication and therefore is not a mere result of plasmid longevity. Slower clearance of BPS/C\textsuperscript{null} compared to other replication-deficient mutants suggests involvement of HBcAg/HBeAg in clearance, as previously reported using HBV plasmids containing AAV sequences\textsuperscript{12,17}. Lowering injection doses has been linked with delayed clearance in certain HBV mouse models, suggesting effects of HBV replication level on host response\textsuperscript{15}. However, clearance of serum HBsAg was also comparable to BPS/P\textsuperscript{null} and BPS/E\textsuperscript{null}, but still faster than BPS. Only about 20% of BPS/M\textsuperscript{plus}, injected mice remained positive for serum antigens at 16 w.p.i. (Fig. 3e). Apparently, this notable variation only partially contributes toward persistence.

Thirdly, HBx ORF was obliterated to create BPS/X\textsuperscript{null}, which displayed markedly lower levels and quicker clearance of serum antigens compared to BPS and most other BPS-derived mutants, with HBsAg disappearing in all mice by 8 w.p.i. and HBeAg disappearing in all but one (n = 12) mice by 10 w.p.i. (Fig. 3d, e). Co-injection of BPS/X\textsuperscript{null} with BPS or B6 HBx resulted in markedly increased levels and extended presence of serum HBsAg and HBeAg, but by 16 w.p.i. these markers had dropped to detection limit levels in all co-injected mice (Supplementary Fig. 11). HBx is clearly necessary but not sufficient for full BPS persistence.

Finally, a series of chimeric constructs between BPS and B6 were constructed, but none of these displayed BPS-like persistence in HDI mice (Supplementary Figs. 12, 13). Taken together, these data demonstrated that replication and multiple viral features jointly contribute to persistence.
BPS persistence correlates with failed immune response. Next, mouse responses to BPS vs. B6 and B200 were compared to identify host processes and factors affecting persistence vs. clearance. In athymic nude mice, BPS, B6 and B200 all persist for >6 w.p.i., demonstrating the necessity of immune competence for clearance (Supplementary Fig. 14). In immunocompetent mice, similar to previous reports1,12, correlation between HBsAb emergence and HBsAg clearance was clearly observed: HBsAb appeared quickly in B6-injected and B200-injected mice, roughly coinciding with HBsAg decrease and clearance (Supplementary Fig. 15), whereas 60% (n = 5) of BPS-injected mice failed to develop HBsAb by 12 w.p.i. and serum HBsAg persisted (Fig. 4), reproducing results in Fig. 1. The other two BPS HDI mice seroconverted to HBsAb at 4 and 10 w.p.i., respectively, with nearly concurrent disappearance of HBsAg (Fig. 4). For cellular responses, at 5 w.p.i., splenocytes from B6-injected mice contain more HBsAg-specific IFN-γ-producing cells than BPS-injected mice (Supplementary Fig. 16). Therefore, BPS persistence correlates with host’s failure to mount certain aspects of humoral and cellular responses. Accordingly, pre-exposure HBsAg vaccination induced HBsAb in all vaccinated mice and prevented BPS from establishing persistence (Fig. 4b, c). In contrast, HBsAg immunisation of mice with pre-established BPS persistence failed to induce HBsAb or clearance (Supplementary Fig. 17), indicating a state of immune tolerance not breakable by conventional vaccination, similar to human chronic infections24.

IL-21 and IL-33 are associated with HBV clearance in mice. As cytokines play essential roles in both innate and adaptive immune responses, why mice responded differently to BPS was studied by comparing serum cytokine profiles of BPS-injected and B6-injected mice using Multiplex technology. Time points between 1 and 32 d.p.i. were selected, as serum HBV antigens have been cleared in B6-injected mice, but persist at considerable levels in BPS-injected mice at 4 w.p.i. (Fig. 1). TNF-α responses in vector-, BPS-injected and B6-injected mice were largely similar, whereas B6-injected mice displayed stronger IL-2, 4, 6 and 10 induction than BPS-injected mice (Supplementary Fig. 18). Most notably, IL-21 and IL-33 were not induced in vector-injected or BPS-injected mice, but strongly induced in B6-injected mice, peaking at 1–2 w.p.i. and reverting to normal levels by about 4 w.p.i. (Fig. 5). Post-exposure induction of IL-21 and IL-33 was also observed in B200, genotype A, as well as BPS/M957 HDI mice (Supplementary Figs. 19, 20). Clearly, robust IL-21 and IL-33 responses to acute HBV exposure correlates with clearance in HDI mice. A similar association between IL-21 and clearance has been shown in another HBV mouse model18 and chronic human infections25–27.

IL-21 and IL-33 functionally contribute towards clearance. To probe whether IL-21 and IL-33 actively participate in HBV clearance, B6-injected mice were subjected to repeated injections of anti-IL-21 or anti-IL-33 antibodies immediately. Mice treated with normal IgG controls cleared serum HBsAg and HBeAg by 2 and 4 w.p.i., similar to untreated mice (Fig. 1), whereas anti-IL-21 or anti-IL-33 injection notably alleviated the decrease and delayed the clearance of serum antigens by 2–4 weeks (Supplementary Fig. 21). Similar effects were observable when B6, B200 and genotype A HDI mice were subjected to repeated injections of combined anti-IL-21 and anti-IL-33 antibodies (Supplementary Figs. 22–24). Conversely, single injection with plasmids expressing mouse IL-21 or IL-33 (Supplementary Fig. 25) immediately
Fig. 3 Comparison between BPS and BPS-derived mutants in vitro and in vivo. BPS and BPS-derived mutants with prematurely terminated C (C<sup>εnull</sup>), X (X<sup>εnull</sup>), or P (P<sup>εnull</sup>) ORFs, re-instated preS2 start codon (M<sup>εpreS2</sup>) or inactivated packaging signal (ε<sup>vesnull</sup>) were transfected into Huh-7 cells and supernatants were assayed for HBsAg (a) and HBeAg (b) at 48 hrs post transfection. c Intracellular capsid-associated HBV DNA was analysed in Southern blot, and quantified using densitometry scanning. Transfection efficiency was normalised by measuring luciferase expressed from co-transfected pGL3 plasmid and data were further normalised taking BPS measurements as 1. Transfections were performed in triplicates and repeated twice independently. Means and s.e.m. of the two repeats are plotted. c top panel shows representative Southern blot results. Plasmids were then used for HDI procedure on BALB/c mice. Sera were collected at indicated time points and analysed for HBsAg (d) and HBeAg (e). Group means and s.e.m. within group (left panels), as well as group positivity percentage data (right panels) are plotted with group sizes (n) indicated. Mutants’ data are compared against wild type and statistical significance calculated using unpaired two-tailed t-test (a, b, c, bottom panel) or log-rank (Mantel–Cox) test (d, e, right panels). *p < 0.05; **p < 0.01; ***p < 0.001. Dotted lines represent cut-off thresholds. w.p.i. weeks post injection

after B6 or B200 HDI procedure slightly but noticeably facilitated decrease and clearance of serum HBV markers (Supplementary Figs. 26, 27). In contrast, single injection of IL-21 or IL-33 expression plasmids immediately after BPS HDI only marginally affected serum levels of HBsAg, HBeAg and HBV DNA, without markedly affecting persistence (Fig. 1; Supplementary Fig. 28). These data proved that IL-21 and IL-33, along with other factors, indeed actively contribute to HBV clearance in acute exposure.

**IL-21 and IL-33 induce clearance of BPS persistence.** We went on to test possible effects of IL-21 and IL-33 on established HBV persistence and hydrodynamically injected IL-21 or IL-33 expression plasmids into BPS HDI mice at 4 w.p.i, when BPS had established persistence while B6/B200 would have been cleared (Fig. 1), and once again at 7 w.p.i. Heightened serum IL-21 and IL-33 levels (Fig. 6a; Supplementary Fig. 29) correlated with decrease of serum HBV markers (Fig. 6b–d). More importantly, viral clearance rate was markedly improved: by around 8 w.p.i., 4 of 6 (67%) IL-21-treated mice had cleared serum HBV antigens, while 5 of 6 (83%) IL-33-injected mice cleared both HBV antigens by 14 w.p.i (Fig. 6b–d). Similarly, HBV DNA in pooled sera decreased rapidly following IL-21 or IL-33 treatments and dropped to detection limit levels by 14 w.p.i. (Fig. 6e). In contrast, 83 and 67% of mice injected with control plasmid failed to clear HBsAg and HBeAg by 14 w.p.i, respectively (Fig. 6b–d), comparable to untreated mice (Fig. 1). Combined injection of IL-21 and IL-33 plasmids displayed no significant additive effects compared to single injections (Supplementary Fig. 30). Treatment-induced disappearance of serum HBV markers was confirmed to be true clearance, instead of cytokine-induced repression of persisting BPS plasmid DNA (Supplementary Fig. 6), by analysing intrahepatic HBV DNA of responder and non-responder BPS mice (Supplementary Fig. 31).

**Histochemistry examination of liver sections showed more prominent immune infiltration in IL-21/IL-33 treated BPS HDI mice compared to mock treated controls and in responder mice, the infiltration apparently lasted longer (Supplementary Fig. 32). It appears that although exogenous IL-21 and IL-33 have limited repressive effects during acute phase of BPS exposure (Supplementary Fig. 28), treatments during chronic phase are highly effective and induce clearance in a majority of recipients. Furthermore, IL-21 and IL-33 were tested on another mouse model of HBV persistence. C57BL/6 mice were injected via HDI with pAAV/HBV containing genotype A HBV genome and AAV-derived sequences<sup>12</sup>. At 4 w.p.i. ~ 60% injected mice failed to clear serum HBV antigens and these mice were injected with IL-21 and IL-33 plasmids in the same way as BPS HDI mice. Accelerated decrease and improved clearance of HBV markers, similar to but less markedly than in BPS mice, were observed (Supplementary Fig. 33). These data demonstrated that effects of IL-21 and IL-33 are not BPS, genotype B or BALB/c specific.

**IL-21-induced and IL-33-induced clearance confers protection.** Autonomous clearance of HBV in HDI mice correlates with HBsAb seroconversion (Fig. 4; Supplementary Fig. 15). In IL-21 and IL-33 treated BPS HDI mice that cleared HBV markers, however, only 1 of 4 and 2 of 5 mice developed HBsAb, respectively (Fig. 6c), indicating the effects of IL-21 and IL-33 on BPS are HBsAb-independent. More surprisingly, when mice that cleared BPS in response to IL-21 or IL-33 were re-challenged with BPS, no persistence was observed: all mice cleared HBsAg and HBeAg within a week (Fig. 7). Once again, there was no marked seroconversion to HBsAb: only 1 of 4 IL-21-cured and 1 of 3 IL-33-cured mice developed HBsAb after re-challenge (Fig. 7a, b). Apparently IL-21 and IL-33 induce a lasting
HBsAb-independent functional resistance to HBV, suggesting new prophylactic and therapeutic possibilities.

**Discussion**

HBV does not infect mouse hepatocytes and consequently, transfection-based mouse models of HBV, including HDI mice, do not reflect full viral life cycle. Nevertheless, these models enable analysis and comparison of virus-host interactions in mice and human. Unlike previously reported mouse models of HBV persistence, BPS persists in common immunocompetent mice without requiring non-HBV viral elements. Persistence is highly strain-specific (Fig. 1; Supplementary Fig. 3), whereas no strain-outcome association has been confirmed in human HBV infections. Human genetic heterogeneity might be a factor at work here, but BPS can persist in at least two diverse mouse strains: BALB/c (H-2d) and C57BL/6 (H-2b) (Fig. 1; Supplementary Fig. 7). Conceivably, capability of most, if not all, HBV strains to establish chronicity in human reflects evolutionary adaptation to its natural host. In this sense, BPS represents an exception compared to the majority of HBV strains that the non-natural host, namely mouse, quickly clears. Identification of such an exception offers a unique opportunity for studying mechanisms mediating HBV clearance and persistence in a tractable in vivo system, with no interference from non-HBV viral sequences.

**Fig. 4** Relation between autonomous viral clearance in BPS HDI mice and serum HBsAb. a Sera from BPS HDI BALB/c mice were individually analysed for HBsAg (left panel) and HBsAb (right panel) using ELISA. Naive mice were then vaccinated with recombinant HBsAg in three doses at 4, 2 and 1 week(s) (arrows) prior to BPS HDI procedure. Sera were collected at indicated time points and analysed for HBsAg (b), HBsAb (c) and HBeAg (d) using ELISA. Group means and s.e.m. within group are presented with group sizes (n) indicated. Dotted lines represent cut-off thresholds. w.p.i. weeks post injection.
Fig. 5 Serum IL-21 and IL-33 are stimulated in B6 HDI mice but not BPS HDI mice. Sera from BPS, B6 and pUC18 HDI BALB/c mice were collected at indicated time points and levels of selected cytokines quantitated using multiplex-based assay. Group means and s.e.m. within group of serum IL-21 (a) and IL-33 (b) measurements are presented with group sizes (n) indicated. BPS and B6 mice data are compared against pUC18 mice and statistical significance calculated using unpaired two-tailed t-test. *p < 0.05; **p < 0.01. For data on other tested cytokines, see Supplementary Fig. 18. w.p.i. weeks post injection

variation, and targeted mutations and segment swapping showed that multiple BPS features simultaneously contribute towards persistence (Fig. 3; Supplementary Figs. 12, 13). Other HBV strains with combined features enabling BPS-like persistence in HDI mice could exist, but previous data and our results suggest that such strains could be rare.

At functional level, BPS displayed higher HBsAg expression and lower replication in transfected cells (Fig. 2), but in HDI mice, serum HBsAg levels during acute phase (0-2 w.p.i.) were comparable between BPS and B6/B200 (Fig. 1a), while serum HBV DNA levels correlated with replication competences in vitro, with BPS being the lowest (Figs. 1c, 2c). Whether lower replication plays any part in BPS persistence is uncertain, but our data suggested that low(er) replication alone is not a decisive factor: BPS-derived mutants BPS/Xnull and BPS/Mplus displayed decreased replication (Fig. 3c), but were cleared more quickly (Fig. 3d, e), and BPS-B6 chimeras displaying lower-than-B6, BPS-like replication competence were all cleared within 8 w.p.i. (Supplementary Figs. 12, 13). Furthermore, BPS at increased or reduced HDI dosage still causes persistence (Supplementary Fig. 10).

Interestingly, despite its comparatively lower replication competence, BPS requires replication to persist in HDI mice (Fig. 3). As HBV does not infect mouse hepatocytes, replication could not promote persistence through expanding infection. Intracellular BPS replication and exported mature virions may directly or indirectly hinder host responses that clear transfected hepatocytes. Since such processes are not unique to BPS, the singular persistence of BPS suggests that persistence-related BPS features discussed above are more important.

Viral factors need to work through affecting host responses to engender persistence, as reflected in the facts that BPS, B6 and B200 all persist in athymic nude mice (Supplementary Fig. 14), whereas BPS is quickly cleared in HBsAg-vaccinated immunocompetent mice (Fig. 4). Humoral and cellular responses to BPS vs. B6 are expectedly different (Fig. 4; Supplementary Fig. 16), but more note-worthy differences were observed in cytokine profiles (Fig. 5; Supplementary Fig. 18). Identification of IL-21 and IL-33 as under-stimulated in BPS HDI mice (Fig. 5; Supplementary Figs. 19, 20) echoes previous observations implicating IL-21 in HBV persistence in young mice and human adults25-27. Mechanistic involvement of IL-21 and IL-33 in HBV clearance is supported by effects of administrating antibodies or expression plasmid during acute phase in HDI mice injected with B6 or other quickly cleared strains (Supplementary Figs. 21-24, 26, 27), and most interestingly, by IL-21-induced and IL-33-induced clearance of pre-established BPS persistence (Fig. 6). Elucidating the origins and targets of IL-21 and IL-33, BPS-specific features preventing or counteracting their induction, and the underlying mechanisms warrants immediate efforts. Since there is no cross-induction between IL-21 and IL-33 (Fig. 6a), and no significant additive or synergistic effects were observable when both interleukins were blocked or administered (Supplementary Figs. 21, 22, 30), it’s likely that these factors independently act through similar downstream processes to induce clearance. Our preliminary results showed that treatment with these cytokines induced immune infiltration in liver of mice harbouring BPS persistence and prolonged infiltration is apparently associated with eventual clearance (Supplementary Fig. 32). Admittedly, cytokines untested here, including but not limited to those shown in Supplementary Figs. 16, 18, may also be important either individually or collectively, but IL-21-induced and IL-33-induced clearance of BPS persistence suggested that these two alone can cause pivotal changes in host responses. Similar effects of IL-21 and IL-33 in another HBV persistence mouse model (Supplementary Fig. 33) reconfirmed them as potent regulators of HBV clearance.

HBsAb seroconversion is a recognised hallmark of recovery and protection in both human and animals2,3. The finding that IL-21-induced or IL-33-induced BPS clearance is HBsAb-independent (Fig. 6), but engenders lasting protection (Fig. 7) is both surprising and promising. Understanding the cellular and molecular nature of such clearance and protection may reveal new aspects of anti-HBV host responses with prophylactic and therapeutic relevance. Meanwhile, these data support IL-21 and IL-33 as valid drug candidates for immunotherapy of chronic HBV infections. These can be used, after taking into consideration potential immune-related side-effects and establishment of corresponding counter-measures, either alone or in combination with antiviral chemotherapy that reduces viral load, as in BPS model IL-21 or IL-33 administration during persistence with reduced viral activity was more effective compared to administration during acute phase (Fig. 6 and Supplementary Fig. 28). On the other hand, it is also possible that a more optimised administration scheme, which could additionally involve other potentially clearance-related immune regulator(s) as discussed above, might enable IL-21 or IL-33 to produce improved results in acute exposure as well.

Methods
HBV plasmids and antibodies. GenBank Accession Numbers of HBV strains used and clinical data on origin of patients are listed in Supplementary Table 1. BPS was previously reported28. B200 and B6 were isolated from patients of Huashan Hospital with informed consent obtained in compliance with requirements of Huashan Hospital Bioethics Committee (Permit No. KY2014-024). Genotype D strain was a gift from Dr. Yongxiang Wang, Fudan University, and other strains were chemically synthesised. HDI plasmids were constructed by cloning ~1.3 fold over-length
**Fig. 6** IL-21 or IL-33 treatments induce clearance of established BPS persistence. Plasmids expressing murine IL-21 or IL-33 and empty vector control were injected into BPS HDI mice at 4 and 7 weeks post injection (w.p.i.) (arrows). Sera were collected at indicated time points and levels of IL-21 and IL-33 (a), HBsAg (b), HBsAb (c) and HBeAg (d) were analysed using ELISA. Group means and s.e.m. within group are presented with group sizes (n) indicated. Group positivity percentage data are also presented for HBsAg (b, right panel), HBsAb (c, right panel) and HBeAg (d, right panel). HBV DNA for each group were analysed using pooled serum in commercial quantitative assay (e). Dotted lines represent cut-off thresholds (a, b–d, right panels) and lower limit of quantification (e) respectively. geq genome equivalents.
HBV genome into pUC18 (Takara, China) (Supplementary Fig. 1a). BPS/Xnull, BPS/Pnull and BPS/Cnull were created by prematurely terminating X, P and C ORFs (Supplementary Fig. 1b, d). BPS/cnull was created by introducing inactivating mutations23 in ε packaging signal (Supplementary Fig. 1c, d). Mutations were designed to change overlapping ORF(s) only synonymously. BPS/M was created by introducing V1M mutation into preS2 ORF, with concurrent R300H mutation downstream of CMV promoter and FLAG tag in pCMV-N-Flag vector (Beyotime, Manassas, VA) cells were performed as previously described22,29. Secreted HBV capsids were quantified using ELISA. Dotted lines represent cut-off thresholds. w.p.i. weeks post injection of BPS re-challenge.

Transfection and analysis of HBV markers and virions. Culture and transfection

HBV genome into pUC18 (Takara, China) (Supplementary Fig. 1a). BPS/Xnull, BPS/Pnull and BPS/Cnull were created by prematurely terminating X, P and C ORFs (Supplementary Fig. 1b, d). Mutations were designed to change overlapping ORF(s) only synonymously. BPS/M was created by introducing V1M mutation into preS2 ORF, with concurrent R300H mutation downstream of CMV promoter and FLAG tag in pCMV-N-Flag vector (Beyotime, China) to create pBPSX and pB6X. Xnull mutation was introduced into pB6X to create pB6X. Luciferase-expressing pGL3 (Promega, China) was used as transfection control. HBV HDI plasmid harbouring AAV sequences (pAAV/HBV) was a gift from Professor Pei-Jer Chen, National Taiwan University12. Mouse IL-21 and IL-33 expression plasmids (Sino Biologics, China) were purchased.

Mice work. Male 6-week-old to 8-week-old specific pathogen-free BALB/c and C57BL/6 mice were purchased from Experimental Animal Centre, Fudan University. Group sizes were chosen generally based on Mead’s resource equation. No blinding or special randomisation was used. For HDI, 10 μg HBx of BPS and B6 were cloned into preS2 ORF, with concurrent R300H mutation downstream of CMV promoter and FLAG tag in pCMV-N-Flag vector (Beyotime, China) to create pBPSX and pB6X. Xnull mutation was introduced into pB6X to create pB6X. Luciferase-expressing pGL3 (Promega, China) was used as transfection control. HBV HDI plasmid harbouring AAV sequences (pAAV/HBV) was a gift from Professor Pei-Jer Chen, National Taiwan University12. Mouse IL-21 and IL-33 expression plasmids (Sino Biologics, China) were purchased.
injected through HDI with 25 μg plasmid expressing murine IL-21 or IL-33. IL-treated BD (HDI) mice displaying >4 week HBsAg negativity were re-challenged as initial HDI. For pAAV/HBV model, C57BL/6 mice were injected via HDI with 10 μg pAAV/HBV and at 4 i.p., mice with positive serum HBV antigens were selected and injected with interleukin plasmids as above. Sera were collected through retro-orbital sinus bleeding, and tissues were collected after sacrifice by cervical dislocation. Mouse procedures were approved by the Animal Ethics Committee of School of Basic Medical Sciences, Fudan University.

**Serum analyses.** Serum HBsAg, HBeAg and HBsAb levels were analysed using ELISA (KHB, China), initially validated by commercial quantitative assays (Adicon, China) in parallel (Supplementary Fig. 2). Serum HBV DNA and ALT were analysed using commercial quantitative assays (Adicon, China). Cyto-kine profiling was performed using Milliplex multiplex assay (Merck Millipore, China) on a Luminex 200 (Luminex, China). Data and statistical analysis as indicated. Group positivity percentages are presented as Kaplan-Meier plot and Mouse data are presented as group means and s.e.m. or for each mouse individually.

**Data and statistical analysis.** ELISA and scanned Southern blot data were first normalised for transfection variation using luciferase readings and then normalised for transfection variation using luciferase readings and then normalised.

**References**

1. Seeger, C. & Mason, W. S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64, 51–68 (2000).
2. Liang, T. J. Hepatitis B: the virus and disease. Hepatology 49, S13–S21 (2009).
3. Ganne, B. & Prince, A. M. Hepatitis B virus infection—natural history and clinical outcomes. N. Engl. J. Med. 350, 1118–1129 (2004).
4. McMahon, B. J. The natural history of chronic hepatitis B virus infection. Hepatology 49, S45–S55 (2009).
5. World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 (2016).
6. Thung, S. N. et al. Animal model of human disease. Chimpanzee carriers of hepatitis B virus. Chimpanzee hepatitis B carriers. Am. J. Pathol. 105, 328–332 (1981).
7. Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1, e00049 (2012).
8. Publicover, J. et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J. Clin. Investig. 121, 1154–1162 (2011).
9. Publicover, J. et al. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J. Clin. Investig. 123, 3728–3739 (2013).
10. Chou, H. et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc. Natl. Acad. Sci. USA 112, 2175–2180 (2015).
11. Yang, P. L., Althage, A., Chung, I. & Chisari, F. V. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 99, 13825–13830 (2002).
12. Huang, I. R., Wu, H. L., Chen, P. J. & Chen, D. S. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 103, 17862–17867 (2006).
13. Karstensen, V. V., Hodgson, A. J., Madden, C. R. & Edgale, B. L. Enhancement of hepatitis B virus replication by the regulatory X protein in vitro and in vivo. J. Virol. 81, 2566–2562 (2007).
14. Chui, X. et al. Lenti viral backbone-based hepatitis B virus replicon-mediated transfer favours the establishment of persistent hepatitis B virus infection in mice after hydrodynamic injection. Antivir. Res. 101, 68–74 (2014).
15. Du, Y. et al. Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice. Gastroenterology 142, 1447–1450 (2012).
16. Huang, Y. H. et al. A murine model of hepatitis B-associated hepatocellular carcinoma generated by adenovirus-mediated gene delivery. Int. J. Oncol. 39, 1511–1519 (2011).
17. Lin, V. I. et al. Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc. Natl. Acad. Sci. USA 107, 9340–9345 (2010).
18. Yang, P. L. et al. Immunometric effectors required for hepatitis B virus clearance. Proc. Natl. Acad. Sci. USA 107, 798–802 (2010).
19. Dion, S., Bourjine, M., Godon, O., Levillayer, F. & Michel, M. L. Adenovirus- mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules. J. Virol. 87, 5554–5563 (2013).
20. Martin, P. et al. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV- persistent mice. Gut 64, 1961–1971 (2015).
21. Abraham, T. M. & Loeb, D. D. The topology of hepatitis B virus pregenomic RNA promotes its replication. J. Virol. 81, 1157–11584 (2007).
22. Zhao, X. et al. Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS. J. Proteome Res. 13, 5391–5402 (2014).
23. Tang, H. et al. The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J. Virol. 79, 5548–5556 (2005).
24. Michel, M. L., Deng, Q. & Mancini-Bourjine, M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J. Hepatol. 54, 1286–1296 (2011).
25. Ma, S. W. et al. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg serocconversion in chronic hepatitis B. J. Hepatol. 56, 775–781 (2012).
26. Li, Y. et al. Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen serocconversion through IL-21 in patients with chronic hepatitis B virus infection. Hepatology 58, 1277–1286 (2013).
27. Li, J. et al. Interleukin-21 responses in patients with chronic hepatitis B. J. Interferon Cytokine Res. 35, 134–142 (2015).
28. Wu, L. et al. Functional comparison of two full-length genomes of hepatitis B virus strains isolated from two chronic hepatitis B patients. Chin. J. Virol. 16, 116–122 (2000).
29. Hong, R. et al. Novel recombinant hepatitis B virus vectors efficiently deliver protein and RNA encoding genes into primary hepatocytes. J. Virol. 87, 6615–6624 (2013).

**Acknowledgements**

We thank Dr. Yong-jiang Wang and Prof. Di Qu, Qiang Deng for providing genotype D strain, HBV transgenic mice and recombinant HBsAg, and Prof. Pei Jer Chen for providing pAAV/HBV, respectively. This work was supported by NSFC (31670166, 81472226, 8146130019, 81471933 and 81672090), the National Science and Technology Major Project for Infectious Diseases (2012ZX10002-006 and 2013ZX10002-001), ‘973’ Project (2012CB519002), and Shanghai Municipal Education Commission program (2017-01-07-00-07-E00057). The funding sources were not involved in study design, collection, analysis and interpretation of data, or writing of the report, or the decision to submit the article for publication.
Author contributions
Z.S., Y.X. and J.L. designed the experiments and wrote the article. Z.S., H.Y., S.Y., W.W., X.C. and X.Z. performed the experiments. W.L, S.P., Y.L. and J.Z. contributed to data analyses.

Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-017-02304-7.

Competing interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.